Literature DB >> 16483850

NADPH oxidase and heart failure.

Colin E Murdoch1, David J Grieve, Alison C Cave, Yee Hoo Looi, Ajay M Shah.   

Abstract

Reactive oxygen species play important roles in the pathophysiology of chronic heart failure secondary to chronic left ventricular hypertrophy or myocardial infarction. Reactive oxygen species influence several components of the phenotype of the failing heart, including contractile function, interstitial fibrosis, endothelial dysfunction and myocyte hypertrophy. Recent studies implicate the production of reactive oxygen species by a family of NADPH oxidases in these effects. NADPH oxidases are activated in an isoform-specific manner by many pathophysiological stimuli and exert distinct downstream effects. Understanding NADPH oxidase activation and regulation, and their downstream effectors, could help to develop novel therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16483850     DOI: 10.1016/j.coph.2005.10.008

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  15 in total

Review 1.  Hyperlipidemia: a new therapeutic target for diabetic neuropathy.

Authors:  Andrea M Vincent; Lucy M Hinder; Rodica Pop-Busui; Eva L Feldman
Journal:  J Peripher Nerv Syst       Date:  2009-12       Impact factor: 3.494

2.  An oxidized extracellular oxidation-reduction state increases Nox1 expression and proliferation in vascular smooth muscle cells via epidermal growth factor receptor activation.

Authors:  Bojana Stanic; Masato Katsuyama; Francis J Miller
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-09-02       Impact factor: 8.311

Review 3.  Perspectives and challenges of antioxidant therapy for atrial fibrillation.

Authors:  Iveta Gasparova; Peter Kubatka; Radka Opatrilova; Martin Caprnda; Slavomira Filipova; Luis Rodrigo; Leone Malan; Ioana Mozos; Miroslava Rabajdova; Vladimir Nosal; Nazarii Kobyliak; Vanda Valentova; Daniel Petrovic; Mariusz Adamek; Peter Kruzliak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-11-29       Impact factor: 3.000

4.  NADPH oxidase inhibition ameliorates cardiac dysfunction in rabbits with heart failure.

Authors:  Yu Liu; He Huang; Wenfang Xia; Yanhong Tang; Haitao Li; Congxin Huang
Journal:  Mol Cell Biochem       Date:  2010-06-22       Impact factor: 3.396

5.  Activation of cAMP-dependent signaling induces oxidative modification of the cardiac Na+-K+ pump and inhibits its activity.

Authors:  Caroline N White; Chia-Chi Liu; Alvaro Garcia; Elisha J Hamilton; Karin K M Chia; Gemma A Figtree; Helge H Rasmussen
Journal:  J Biol Chem       Date:  2010-03-01       Impact factor: 5.157

Review 6.  The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias.

Authors:  Shahriar Iravanian; Samuel C Dudley
Journal:  Heart Rhythm       Date:  2008-03-04       Impact factor: 6.343

7.  Sodium tanshinone IIA sulfonate attenuates angiotensin II-induced collagen type I expression in cardiac fibroblasts in vitro.

Authors:  Le Yang; Xiao-Jing Zou; Xiang Gao; Hao Chen; Jin-Long Luo; Zhao-Hua Wang; Qian-Sheng Liang; Guang-Tian Yang
Journal:  Exp Mol Med       Date:  2009-07-31       Impact factor: 8.718

Review 8.  The Mystery of Diabetic Cardiomyopathy: From Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities.

Authors:  Petra Grubić Rotkvić; Zrinka Planinić; Ana-Marija Liberati Pršo; Jozica Šikić; Edvard Galić; Luka Rotkvić
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

9.  Protection against ischemia-induced oxidative stress conferred by vagal stimulation in the rat heart: involvement of the AMPK-PKC pathway.

Authors:  Shan-Shan Kong; Jin-Jun Liu; Xiao-Jiang Yu; Yi Lu; Wei-Jin Zang
Journal:  Int J Mol Sci       Date:  2012-11-05       Impact factor: 5.923

10.  Role of NADPH oxidase in H9c2 cardiac muscle cells exposed to simulated ischaemia-reperfusion.

Authors:  Elisabetta Borchi; Matteo Parri; Laura Papucci; Matteo Becatti; Niccolò Nassi; Paolo Nassi; Chiara Nediani
Journal:  J Cell Mol Med       Date:  2009-08       Impact factor: 5.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.